vs
吉利德科学（GILD）与皇家加勒比集团（RCL）财务数据对比。点击上方公司名可切换其他公司
吉利德科学的季度营收约是皇家加勒比集团的1.9倍（$7.9B vs $4.3B），吉利德科学净利率更高（27.5% vs 17.7%，领先9.9%），皇家加勒比集团同比增速更快（13.3% vs 4.7%），吉利德科学自由现金流更多（$3.1B vs $116.0M），过去两年吉利德科学的营收复合增速更高（8.9% vs 6.9%）
吉利德科学是总部位于美国加利福尼亚州福斯特城的生物制药企业，专注于研发抗病毒药物，覆盖艾滋病、乙型肝炎、丙型肝炎、流感、新冠等治疗领域，核心产品包括来迪派韦索磷布韦、索磷布韦等，现为纳斯达克100指数及标普100指数成分股。
皇家加勒比集团前身为皇家加勒比邮轮有限公司，是仅次于嘉年华公司的全球第二大邮轮运营商。集团总部位于美国佛罗里达州迈阿密，在利比里亚注册，目前全资拥有皇家加勒比国际游轮、名人邮轮、银海邮轮三大品牌，还持有途易邮轮50%的股份。
GILD vs RCL — 直观对比
营收规模更大
GILD
是对方的1.9倍
$4.3B
营收增速更快
RCL
高出8.6%
4.7%
净利率更高
GILD
高出9.9%
17.7%
自由现金流更多
GILD
多$3.0B
$116.0M
两年增速更快
GILD
近两年复合增速
6.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $7.9B | $4.3B |
| 净利润 | $2.2B | $753.0M |
| 毛利率 | 79.5% | 47.4% |
| 营业利润率 | 25.0% | 21.9% |
| 净利率 | 27.5% | 17.7% |
| 营收同比 | 4.7% | 13.3% |
| 净利润同比 | 22.4% | 36.4% |
| 每股收益（稀释后） | $1.75 | $2.76 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GILDRCL
| Q4 25 | $7.9B | $4.3B | ||
| Q3 25 | $7.8B | $5.1B | ||
| Q2 25 | $7.1B | $4.5B | ||
| Q1 25 | $6.7B | $4.0B | ||
| Q4 24 | $7.6B | $3.8B | ||
| Q3 24 | $7.5B | $4.9B | ||
| Q2 24 | $7.0B | $4.1B | ||
| Q1 24 | $6.7B | $3.7B |
净利润GILDRCL
| Q4 25 | $2.2B | $753.0M | ||
| Q3 25 | $3.1B | $1.6B | ||
| Q2 25 | $2.0B | $1.2B | ||
| Q1 25 | $1.3B | $730.0M | ||
| Q4 24 | $1.8B | $552.0M | ||
| Q3 24 | $1.3B | $1.1B | ||
| Q2 24 | $1.6B | $854.0M | ||
| Q1 24 | $-4.2B | $360.0M |
毛利率GILDRCL
| Q4 25 | 79.5% | 47.4% | ||
| Q3 25 | 79.8% | 51.8% | ||
| Q2 25 | 78.8% | 49.7% | ||
| Q1 25 | 76.9% | 48.0% | ||
| Q4 24 | 79.1% | 45.4% | ||
| Q3 24 | 79.1% | 51.1% | ||
| Q2 24 | 77.8% | 47.6% | ||
| Q1 24 | 76.8% | 44.8% |
营业利润率GILDRCL
| Q4 25 | 25.0% | 21.9% | ||
| Q3 25 | 42.8% | 33.1% | ||
| Q2 25 | 34.9% | 29.3% | ||
| Q1 25 | 33.6% | 23.6% | ||
| Q4 24 | 32.4% | 16.6% | ||
| Q3 24 | 11.8% | 33.4% | ||
| Q2 24 | 38.0% | 26.7% | ||
| Q1 24 | -64.6% | 20.1% |
净利率GILDRCL
| Q4 25 | 27.5% | 17.7% | ||
| Q3 25 | 39.3% | 30.6% | ||
| Q2 25 | 27.7% | 26.7% | ||
| Q1 25 | 19.7% | 18.3% | ||
| Q4 24 | 23.6% | 14.7% | ||
| Q3 24 | 16.6% | 22.7% | ||
| Q2 24 | 23.2% | 20.8% | ||
| Q1 24 | -62.4% | 9.7% |
每股收益（稀释后）GILDRCL
| Q4 25 | $1.75 | $2.76 | ||
| Q3 25 | $2.43 | $5.74 | ||
| Q2 25 | $1.56 | $4.41 | ||
| Q1 25 | $1.04 | $2.70 | ||
| Q4 24 | $1.43 | $2.27 | ||
| Q3 24 | $1.00 | $4.21 | ||
| Q2 24 | $1.29 | $3.11 | ||
| Q1 24 | $-3.34 | $1.35 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $68.0M | $825.0M |
| 总债务越低越好 | $24.9B | $18.2B |
| 股东权益账面价值 | $22.7B | $10.0B |
| 总资产 | $59.0B | $41.6B |
| 负债/权益比越低杠杆越低 | 1.10× | 1.81× |
8季度趋势，按日历期对齐
现金及短期投资GILDRCL
| Q4 25 | $68.0M | $825.0M | ||
| Q3 25 | $19.0M | $432.0M | ||
| Q2 25 | $69.0M | $735.0M | ||
| Q1 25 | — | $386.0M | ||
| Q4 24 | — | $388.0M | ||
| Q3 24 | — | $418.0M | ||
| Q2 24 | — | $391.0M | ||
| Q1 24 | — | $437.0M |
总债务GILDRCL
| Q4 25 | $24.9B | $18.2B | ||
| Q3 25 | $24.9B | $17.2B | ||
| Q2 25 | $24.9B | $17.6B | ||
| Q1 25 | $25.0B | $18.0B | ||
| Q4 24 | $26.7B | $18.5B | ||
| Q3 24 | $23.2B | $19.0B | ||
| Q2 24 | $23.3B | $19.8B | ||
| Q1 24 | $25.2B | $18.9B |
股东权益GILDRCL
| Q4 25 | $22.7B | $10.0B | ||
| Q3 25 | $21.5B | $10.1B | ||
| Q2 25 | $19.7B | $9.2B | ||
| Q1 25 | $19.2B | $8.0B | ||
| Q4 24 | $19.3B | $7.6B | ||
| Q3 24 | $18.5B | $7.0B | ||
| Q2 24 | $18.3B | $6.0B | ||
| Q1 24 | $17.5B | $5.2B |
总资产GILDRCL
| Q4 25 | $59.0B | $41.6B | ||
| Q3 25 | $58.5B | $40.1B | ||
| Q2 25 | $55.7B | $38.5B | ||
| Q1 25 | $56.4B | $37.5B | ||
| Q4 24 | $59.0B | $37.1B | ||
| Q3 24 | $54.5B | $37.1B | ||
| Q2 24 | $53.6B | $37.0B | ||
| Q1 24 | $56.3B | $35.2B |
负债/权益比GILDRCL
| Q4 25 | 1.10× | 1.81× | ||
| Q3 25 | 1.16× | 1.70× | ||
| Q2 25 | 1.27× | 1.92× | ||
| Q1 25 | 1.30× | 2.26× | ||
| Q4 24 | 1.38× | 2.44× | ||
| Q3 24 | 1.26× | 2.69× | ||
| Q2 24 | 1.28× | 3.29× | ||
| Q1 24 | 1.44× | 3.66× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.3B | $1.6B |
| 自由现金流经营现金流 - 资本支出 | $3.1B | $116.0M |
| 自由现金流率自由现金流/营收 | 39.4% | 2.7% |
| 资本支出强度资本支出/营收 | 2.6% | 35.4% |
| 现金转化率经营现金流/净利润 | 1.52× | 2.16× |
| 过去12个月自由现金流最近4个季度 | $9.5B | $1.2B |
8季度趋势，按日历期对齐
经营现金流GILDRCL
| Q4 25 | $3.3B | $1.6B | ||
| Q3 25 | $4.1B | $1.5B | ||
| Q2 25 | $827.0M | $1.7B | ||
| Q1 25 | $1.8B | $1.6B | ||
| Q4 24 | $3.0B | $1.5B | ||
| Q3 24 | $4.3B | $897.0M | ||
| Q2 24 | $1.3B | $1.6B | ||
| Q1 24 | $2.2B | $1.3B |
自由现金流GILDRCL
| Q4 25 | $3.1B | $116.0M | ||
| Q3 25 | $4.0B | $-989.0M | ||
| Q2 25 | $720.0M | $910.0M | ||
| Q1 25 | $1.7B | $1.2B | ||
| Q4 24 | $2.8B | $915.0M | ||
| Q3 24 | $4.2B | $563.0M | ||
| Q2 24 | $1.2B | $-567.0M | ||
| Q1 24 | $2.1B | $1.1B |
自由现金流率GILDRCL
| Q4 25 | 39.4% | 2.7% | ||
| Q3 25 | 51.0% | -19.2% | ||
| Q2 25 | 10.2% | 20.1% | ||
| Q1 25 | 24.8% | 30.0% | ||
| Q4 24 | 37.4% | 24.3% | ||
| Q3 24 | 55.2% | 11.5% | ||
| Q2 24 | 17.2% | -13.8% | ||
| Q1 24 | 31.6% | 29.1% |
资本支出强度GILDRCL
| Q4 25 | 2.6% | 35.4% | ||
| Q3 25 | 1.9% | 47.8% | ||
| Q2 25 | 1.5% | 18.4% | ||
| Q1 25 | 1.6% | 10.7% | ||
| Q4 24 | 1.9% | 14.7% | ||
| Q3 24 | 1.9% | 6.8% | ||
| Q2 24 | 1.9% | 52.1% | ||
| Q1 24 | 1.6% | 6.5% |
现金转化率GILDRCL
| Q4 25 | 1.52× | 2.16× | ||
| Q3 25 | 1.35× | 0.93× | ||
| Q2 25 | 0.42× | 1.44× | ||
| Q1 25 | 1.34× | 2.23× | ||
| Q4 24 | 1.67× | 2.66× | ||
| Q3 24 | 3.44× | 0.81× | ||
| Q2 24 | 0.82× | 1.84× | ||
| Q1 24 | — | 3.69× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GILD
| Other | $3.4B | 43% |
| HIV Products Biktarvy | $3.3B | 41% |
| HIV Products Odefsey | $239.0M | 3% |
| Liver Disease Products Other Liver Disease | $170.0M | 2% |
| HIV Products Other HIV | $155.0M | 2% |
| Other Products Yescarta | $150.0M | 2% |
| Liver Disease Products Vemlidy | $149.0M | 2% |
| Liver Disease Products Sofosbuvir Velpatasvir | $140.0M | 2% |
| HIV Products Symtuza Revenue Share | $98.0M | 1% |
| Veklury | $80.0M | 1% |
| Cell Therapy Products Tecartus | $32.0M | 0% |
| Royalty Contract And Other | $22.0M | 0% |
RCL
| Passenger | $2.9B | 69% |
| Other | $1.3B | 31% |
